KA/EN
Register
Medicines reference
Search
Search
Product

Purevax FeLV

Favourites

Recombinant canarypox virus expressing FeLV antigens (vCP97) · Boehringer Ingelheim Animal Health France SCS

1 form: suspension. In force in Georgia: 1 of 1 (veterinary register).

Forms and doses1 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Form Species Dose Frequency Georgia
7.2 log10 CCID50/dose, Suspension · Cat Cat 0.5 ml
Inject one 0.5 ml dose subcutaneously. Start from 8 weeks and repeat 3-5 weeks later; revaccinate annually. Test for FeLV antigenaemia before vaccination because vaccinating an FeLV-positive cat is of no benefit. Vaccinate healthy cats only. Do not use throughout pregnancy or lactation. Injection-site reactions, transient apathy, anorexia or hyperthermia and hypersensitivity can occur.
 · two-dose primary series, then annual revaccination		 two-dose primary series, then annual revaccination Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: პურევაქსი FeLV
№ 41-11
Verified on: 20 Oct 2026
Details: pack, label wording, sources, registration

Purevax FeLV 7.2 log10 CCID50/dose, Suspension

suspension for injection, 0.5 ml dose for cats
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.4/10
Very good
vetman assessment

Purevax FeLV

suspension for injection, 0.5 ml dose for cats
Assessed clinical scopeCat · Full cat label: active immunisation from 8 weeks against feline leukaemia to prevent persistent viraemia and clinical signs, with a two-dose primary course and annual revaccination · Subcutaneous
Care settingRisk-based preventive vaccination after FeLV testing, with examination, cold-chain control and emergency treatment available
vetman score 8.4/10 Very good
Evidence confidence: Medium Georgia: Yes, veterinary · № 41-11 · Verified on 20 Oct 2026

A credible non-adjuvanted FeLV vaccine for cats whose age or lifestyle justifies protection. Its value depends on negative pre-vaccination testing and genuine exposure risk; mixed exact-product challenge results argue against presenting it as complete protection.

Regulatory and scientific credibility9.0/10

The exact non-adjuvanted recombinant presentation is registered in Georgia and has a current detailed SPC defining the vector, full schedule, indication, adverse events and pre-vaccination testing requirement.

Clinical efficacy7.8/10

Guidelines strongly support FeLV vaccination for kittens and exposure-risk cats, and controlled challenges show protection. Exact-product comparative studies are inconsistent in magnitude, no vaccine is fully protective and vaccination does not benefit an already FeLV-positive cat.

Safety and tolerability8.5/10

The non-adjuvanted recombinant design avoids a traditional adjuvant burden and the expected profile is mainly transient; injection-site reactions, fever, apathy, anorexia and uncommon hypersensitivity remain relevant, and pregnancy or lactation use is contraindicated.

Clinical practicality8.2/10

The fixed 0.5 ml SC dose is simple, but FeLV testing before vaccination, a second dose after 3-5 weeks, annual boosters and repeated exposure-risk review create a justified continuing workflow.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Test for FeLV antigenaemia before vaccination; vaccination has no benefit for a cat already positive for FeLV.
  • Use for kittens and cats with meaningful exposure risk; reassess indoor/outdoor and household risk rather than vaccinating every adult automatically.
  • No FeLV vaccine is fully protective; continue exposure prevention and do not use vaccination to replace testing or infected-cat management.
  • Do not use during pregnancy or lactation.
  • Monitor injection-site reactions, fever, apathy, anorexia and uncommon hypersensitivity; treat systemic reactions promptly.
  • Use other vaccines on the same day only where the product information supports the combination; do not mix in one syringe.
  • Give two 0.5 ml SC doses 3-5 weeks apart, then revaccinate annually while risk persists; maintain cold chain and do not freeze.
Assessment sources
  1. VMD SPC 20262026
  2. WSAVA vaccination 20242024
  3. AAHA/AAFP feline vaccination 20202020
  4. FeLV comparative challenge 20152015
  5. FeLV equal-condition challenge2017
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Recombinant canarypox virus expressing FeLV antigens (vCP97)7.2 log10 CCID50/dose
Formulation Type
Suspension
Administration route
Subcutaneous
Manufacturer (register)
SCS Boehringer Ingelheim Animal Health France SCS, France
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1316, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: პურევაქსი FeLV
№ 41-11
Verified on: 20 Oct 2026
Controlled in Georgia
Unknown
DoseSpeciesWeightRouteFrequencySource
0.5 ml
Inject one 0.5 ml dose subcutaneously. Start from 8 weeks and repeat 3-5 weeks later; revaccinate annually. Test for FeLV antigenaemia before vaccination because vaccinating an FeLV-positive cat is of no benefit. Vaccinate healthy cats only. Do not use throughout pregnancy or lactation. Injection-site reactions, transient apathy, anorexia or hyperthermia and hypersensitivity can occur.
 Cat Any weight Subcutaneous two-dose primary series, then annual revaccination
VMD SPC 2026
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Purevax FeLV - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 21 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗